BPR001-615 / BiPER Therapeutics - LARVOL DELTA

COLBiP: Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas (clinicaltrials.gov) - P=N/A | N=15 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Nice | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

COLBiP: Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas (clinicaltrials.gov) - P=N/A | N=15 | Not yet recruiting | Sponsor: Centre Hospitalier Universitaire de Nice

New trial • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

BPR001-615, an oral selective BIP/GRP78 inhibitor, demonstrates biomarker-informed strong antitumor activity in preclinical gastric cancer models (ESMO-GI 2026) - "14-days GLP-like toxicology studies in rats and dogs showed very good tolerability, with a NOAEL of 360 mg/kg in dogs confirming a therapeutic index of 10.Conclusions BPR001-615 is a first-in-class oral selective BIP inhibitor with a novel mechanism of action. Its biomarker-driven strong antitumor activity, selectivity and excellent tolerability support further development as single-agent targeted therapy to treat >50% of BIP high gastrointestinal cancer patients with a first focus in gastric cancer patients."

Preclinical • Colorectal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CASP3 • HER-2 • HSPA5